Thromb Haemost 1970; 24(01/02): 224-229
DOI: 10.1055/s-0038-1654228
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Assay of Progressive Antithrombin in Plasma

U Abildgaard
1   Haematological Research Laboratory, Dept. IX, Ullevål Hospital, University Clinic, Oslo, Norway
,
K Gravem
1   Haematological Research Laboratory, Dept. IX, Ullevål Hospital, University Clinic, Oslo, Norway
,
H. C Godal
1   Haematological Research Laboratory, Dept. IX, Ullevål Hospital, University Clinic, Oslo, Norway
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Juni 2018 (online)

Summary

A simple two-stage assay of progressive antithrombin activity in plasma is described. After heat defibrination, plasma is diluted VlO in buffer (pH 8.0) and incubated with thrombin for 3 min at 37° C. After incubation, residual thrombin activity is determined with standard substrate (antithrombin clotting time). By substituting buffer for diluted plasma, the buffer clotting time is determined. The antithrombin activity may be calculated from these two clotting times or read from a standard curve. It is expressed in per cent of pooled normal plasma. The range in 36 normal plasmas was 74-116%, the S. D. 11%, and the S. E. M. 5.7%. The combination of simplicity and accuracy makes the present method compare favourably with earlier methods.

 
  • References

  • 1 Astrup T, Darling S. Measurement and proporties of antithrombin. Acta physiol, scand 04: 293 1942;
  • 2 Seegers W. H, Miller K. D, Andrews E. B, Murphy R. G. Fundamental interactions and the effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. Amer. J. Phys 169: 700 1952;
  • 3 Hallen A. A method for measuring antithrombin. Thrombos. Diathes. haemorrh. (Stuttg..) 08: 56 1962;
  • 4 Gerendâs M. Die Thrombinaktivierung als Enzymprozeß. Thrombos. Diathes. haemorrh. (Stuttg..) 04: 56 1960;
  • 5 Hensen A, Loeliger E. A. Antithrombin III. Its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.). 09. Suppl. 1 1963
  • 6 V. Kaulla E, Kaulla K. Nv. Antithrombin III and diseases. Amer. J. clin. Path 48: 69 1967;
  • 7 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos. Diathes. haemorrh. (Stuttg..) 13: 516 1965;
  • 8 AbildgaarcL U. Purification of two progressive antithrombins of human plasma. Scand. J. clin. Lab. Invest 19: 190 1967;
  • 9 Witte S, Dirnberger P. Die getrennte Bestimmung von Thrombininhibitor und Antithrombin. Schweiz, med. Wschr 84: 800 1954;
  • 10 Burstein M, GuinancL A. Fibrine et consommation d’antithrombine Sang. 26: 892 1955;
  • 11 Greep J. M, Loeliger E. A, Roos J. Progressive antithrombin and fibrinogen. The antithrombin time according to Innerfield and its relation to acute pancreatitis. Thromb. Diathes. haemorrh. (Stuttg.) 5: 256 (1961), Antithrombine-vermeerdering bij acute pancreatitis Ned. T. Geneesk 106: 1184 1962;
  • 12 Owren P. A. The coagulation of blood. Acta med. scand 128 Suppl. 194 1947;
  • 13 Soulier J. P. Un nouvel adsorbant des facteurs de coagulation: La bentonite. Rev. Hemat 14: 26 1959;
  • 14 Abildgaard U, Egeberg O. Thrombin inhibitory activity of fractions obtained by gel filtration of antithrombin III deficient plasma. Scand. J. Haemat 05: 155 1968;
  • 15 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand. J. clin. Lab. Invest 21: 89 1968;
  • 16 Blix S, Abildgaard U. Unpublished observations..
  • 17 Fagerhol M. K, Abildgaard U. Immunological studies on antithrombin III. Scand. J. Haemat. (Inpress.)